Subgroup Analysis Shows Dostarlimab/Chemotherapy Elicits PFS

Subgroup Analysis Shows Dostarlimab/Chemotherapy Elicits PFS Benefit in dMMR/MSI-H, TP53+, and NSMP Endometrial Cancer

Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.

Related Keywords

Denmark , Spain , Copenhagen , Køavn , Madrid , Mansoor Raza Mirza , European Society Of Medical Oncology , European Society , Medical Oncology , Dostarlimab , Endometrial Cancer , Esmo Congress , Ruby Trial ,

© 2025 Vimarsana